Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.45) by 73.33 percent. This is a 92.55 percent increase over losses of $(1.61) per share from the same period last year.